William Blair analyst Matt Phipps has maintained their bullish stance on NAMS stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matt Phipps has given his Buy rating due to a combination of factors that highlight NewAmsterdam Pharma Company’s promising outlook. The company’s recent third-quarter earnings report showed strong performance, with shares rising significantly, which can be attributed to their effective execution and anticipation of key developments expected in 2026.
Furthermore, the marketing authorization applications for obicetrapib and its combination with ezetimibe have been accepted for review by the European Medicines Agency. This progress, alongside the upcoming presentation of additional data at a major scientific conference, underscores the potential of obicetrapib in treating patients with specific cholesterol conditions. The anticipated commercial launch in Europe and the competitive positioning against other treatments further reinforce the positive outlook for NewAmsterdam Pharma.
In another report released today, Needham also maintained a Buy rating on the stock with a $46.00 price target.